Treatment of VTE

This is promotional content, intended for UK healthcare professionals only.
This webpage has been developed and funded by the Bristol-Myers Squibb / Pfizer Alliance.

Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.

This section addresses the treatment of patients with confirmed VTE, including:

Anticoagulation for the management of VTE
Initial management of a confirmed VTE
DOACs for the treatment of VTE and prevention of recurrent VTE
Efficacy and safety of DOACs

Adverse events should be reported. Reporting forms and information can be found via United Kingdom – The yellow card scheme at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (United Kingdom).

Previous
Next

In Treatment of VTE: Treatment of VTE | Anticoagulation for the management of VTE | Initial management of a confirmed VTE | DOACs for the treatment of VTE and prevention of recurrent VTE |

Abbreviations

DOAC=Direct-acting Oral Anticoagulant DVT=Deep Vein Thrombosis MHRA=Medicines and Healthcare products and Regulatory Agency PE=Pulmonary Embolism VTE=Venous Thromboembolism

Job code: 432-GB-2100110

Date of preparation: September 2021

Managing and treating patients with VTE

Treatment of VTE

Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.

Abbreviations